Episurf Medical takes the next step in partnership regarding its AI-based imaging technology
Episurf Medical (NASDAQ: EPIS B), a pioneer and leader in individualised technologies for painful joint injuries, today announces that it has entered into an agreement with a US-based orthopaedic company. This company will have exclusive rights to use Episurf Medical’s AI-based medical imaging technology for allograft products in North America and the UK. This agreement follows a Letter of Intent, in which the two companies announced that they had entered into in July 2019. The agreement covers an initial evaluation period during which the potential use of Episurf Medical’s proprietary AI-based imaging technology for surgical planning and optimisation of allograft-related products will be evaluated. The details and financial considerations remain confidential but entering into this specific industry implies a revenue potential for Episurf Medical within the field of imaging.
“We are very happy to take the next step in this partnership, following the letter of intent earlier in July. We are proud of the capabilities of our proprietary imaging technology, and we look forward to applying it in the allograft industry” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 28 August 2019.